Related Experiment Video
Updated: Apr 20, 2026

Pharmacophore Modeling for Targets with Extensive Ligand Libraries: A Case Study on SARS-CoV-2 Mpro
Published on: September 26, 2025
Racing to define pharmaceutical R&D external innovation models
Liangsu Wang1, Andrew Plump2, Michael Ringel3
1Merck Research Laboratories, 2015 Galloping Hill Road, Kenilworth, NJ 07033, USA.
Abstract:
The pharmaceutical industry continues to face fundamental challenges because of issues with research and development (R&D) productivity and rising customer expectations. To lower R&D costs, move beyond me-too therapies, and create more transformative portfolios, pharmaceutical companies are actively capitalizing on external innovation through precompetitive collaboration with academia, cultivation of biotech start-ups, and proactive licensing and acquisitions. Here, we review the varying innovation strategies used by pharmaceutical companies, compare and contrast these models, and identify the trends in external innovation. We also discuss factors that influence these external innovation models and propose a preliminary set of metrics that could be used as leading indicators of success.
More Related Videos
Related Concept Videos
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Pharmacodynamic Models: Overview
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Drug Discovery: Overview
Pharmacokinetic Models: Overview
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...

